1WJD

SOLUTION STRUCTURE OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE (E FORM), NMR, 38 STRUCTURES

SOLUTION NMR

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	DMX600	600
2	Bruker	DMX500	500
3	Bruker	DMX750	750

NMR Refinement
Method	Details	Software
simulated annealing	THE STRUCTURES WERE CALCULATED USING THE SIMULATED ANNEALING PROTOCOL OF NILGES ET AL. (1988) FEBS LETT. 229, 129 - 136 USING THE PROGRAM XPLOR 3.1 (BRUNGER) MODIFIED TO INCORPORATE COUPLING CONSTANT (GARRETT ET AL. (1984) J. MAGN RESON. SERIES B 104, 99 - 103), CARBON CHEMICAL SHIFT (KUSZEWSKI ET AL. (1995) J. MAGN. RESON. SERIES B 106, 92 - 96) RESTRAINTS AND A CONFORMATIONAL DATABASE POTENTIAL (KUSZEWSKI ET AL. (1996) PROTEIN SCI 5, 1067 - 1080 AND (1997) J. MAGN. RESON. 125, 171-177). THE 3D STRUCTURE OF THE N-TERMINAL DOMAIN OF HIV-1 INTEGRASE WAS SOLVED BY MULTI-DIMENSIONAL HETERONUCLEAR-EDITED AND -FILTERED NMR IS BASED ON 851 EXPERIMENTAL RESTRAINTS (PER MONOMER): (A) INTRASUBUNIT: 201 SEQUENTIAL (\|I-J\|=1), 224 MEDIUM RANGE (1 < \|I-J\| >=5) AND 98 LONG RANGE (\|I-J\| >5) INTERRESIDUE, AND 17 INTRARESIDUE APPROXIMATE INTERPROTON DISTANCE RESTRAINTS; 32 DISTANCE RESTRAINTS FOR 16 HYDROGEN BONDS; 91 TORSION ANGLE (45 PHI, 1 PSI, 31 CHI1 AND 14 CHI2) RESTRAINTS; 40 THREE-BOND HN-HA COUPLING CONSTANT RESTRAINTS; 97 (50 CALPHA AND 47 CBETA) 13C SHIFT RESTRAINTS. (B) 28 INTERSUBUNIT INTERPROTON DISTANCE RESTRAINTS. (C) 23 AMBIGUOUS INTERPROTON DISTANCE RESTRAINTS THAT CAN ARISE FROM INTRA AND/OR INTERSUBUNIT INTERACTIONS. THE STRUCTURES IN THIS ENTRY ARE THE 40 SIMULATED ANNEALING STRUCTURES. THE LAST NUMERIC COLUMN IN THE INDIVIDUAL SA STRUCTURES HAS NO MEANING. THE LAST LETTER COLUMN SIGNIFIES THE SUBUNIT (A OR B). RESIDUES 47 - 55 ARE DISORDERED.	X-PLOR

NMR Ensemble Information
Conformer Selection Criteria
Conformers Calculated Total Number	38
Conformers Submitted Total Number	38

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	X-PLOR	3.1	BRUNGER
2	structure solution	X-PLOR MODIFIED	MODIFIED

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.